Sci­ence 37 takes the SPAC short­cut to Nas­daq, land­ing a $235M wind­fall for its push on de­cen­tral­ized tri­als

Sci­ence 37, which bills it­self as a pi­o­neer in the move to de­cen­tral­ized clin­i­cal tri­als, has reached the end of the SPAC trail to Nas­daq.

The life sci com­pa­ny has com­plet­ed its merg­er with LifeSci Ac­qui­si­tion II Corp., a blank check com­pa­ny, that will de­liv­er a $235 mil­lion bonus of cash, less the usu­al slate of fees.

De­cen­tral­ized tri­als have been all the rage in bio­phar­ma, par­tic­u­lar­ly dur­ing the pan­dem­ic as com­pa­nies ad­just­ed to lock­downs and dis­tanc­ing de­mands. But they were trendy even be­fore Covid made them ab­solute­ly nec­es­sary as drug de­vel­op­ers looked for new and bet­ter ways to at­tract a di­verse set of pa­tients for clin­i­cal stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER